<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966664</url>
  </required_header>
  <id_info>
    <org_study_id>ENTERPRISE</org_study_id>
    <nct_id>NCT03966664</nct_id>
  </id_info>
  <brief_title>Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients</brief_title>
  <acronym>ENTERPRISE</acronym>
  <official_title>Determination of Ka of Isolated Plasma and Whole Blood of Critically Ill Patients With Sepsis, Non-septic Patients and Healthy Volunteers: an International, In-vitro Acid-base Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alterations of acid-base equilibrium are very common in critically ill patients and
      understanding their pathophysiology can be important to improve clinical treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acid-base equilibrium has been object of study for more than 100 years in medicine because of
      its relevance in patients' management and in determining their prognosis, especially in the
      ICU.

      A concept closely related to acid-base equilibrium is that of &quot;buffer&quot;, term used to define
      any substance able to limit the changes in pH caused by the addition or loss of alkali or
      acid.

      Depending on its physiochemical features, every buffer has one or more pH (negative logarithm
      of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These
      values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer
      dissolved in solution is half in its associated form (AH) and half in its dissociated form
      (A-).

      Several studies tried to determine the normal values of both concentration and Ka of ATOT.
      However, they did not lead to univocal results. Moreover, many of these values come from
      studies of veterinary medicine or are the result of theoretical estimates on human plasma.

      Staempfli and Constable performed a single experimental study on human plasma in 2003. These
      authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT
      and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients
      with sepsis are still unknown.

      Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of
      isolated plasma of critically ill patients with sepsis, and compare these data with normal
      values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of
      critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH
      variations for a given perturbation of the system (variation in carbon dioxide).

      Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and
      compare these data with normal values, i.e. obtained from healthy controls. The investigators
      hypothesize that blood of critically ill septic patients has a lower Ka and that,
      consequently, it undergoes higher pH variations for a given perturbation of the system
      (variation in carbon dioxide).

      Other aims of the study are:

        -  quantify the Ka of plasma and whole blood of non-septic patients admitted to the ICU and
           compare these results with the values of septic patients and healthy volunteers.

        -  define the normal concentration of weak non-carbonic acids (ATOT) in plasma of septic
           patients and compare it with data obtained in healthy volunteers and non-septic
           patients.

      Finally, possible structural alteration of plasma proteins will be evaluated:

        -  Identification of differentially modified proteoforms of serum albumin and major plasma
           proteins by two-dimensional electrophoresis;

        -  High Performance Liquid Chromatography (HPLC) to identify different Redox-forms of
           albumin

        -  Spectrophotometric evaluation of modifications of ligand binding properties of serum
           albumin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effective dissociation constant of plasma weak acids (Ka) [dimensionless]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in plasma Ka between study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective dissociation constant of whole blood weak acids (Ka) [dimensionless]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in whole blood Ka between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total concentration of plasma non-volatile buffers (Atot) [mmol/L]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in plasma Atot between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total concentration of whole blood non-volatile buffers (Atot) [mmol/L]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in whole blood Atot between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-carbonic buffer power of whole blood due to electrolyte shifts [milliequivalents/L]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in Non-carbonic buffer power of whole blood due to electrolyte shifts between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-carbonic buffer power of isolated plasma due to electrolyte shifts [milliequivalents/L]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in Non-carbonic buffer power of isolated plasma due to electrolyte shifts between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized albumin [%]</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in the percentage in oxidized albumin between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of altered ligand binding properties</measure>
    <time_frame>1 day</time_frame>
    <description>HSA will be fractionated and dissociation constants for warfarin-SA and diazepam-SA complexes will be obtained spectrophotometrically to evaluate modifications in its ligand binding properties</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of differentially modified proteoforms of human serum albumin (HSA) and major plasma proteins.</measure>
    <time_frame>1 day</time_frame>
    <description>Samples will be analyzed by two-dimensional electrophoresis.8 After fluorescent staining and image acquisition, proteoform patterns corresponding to HSA and other major plasma proteins will be aligned and compared</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Critical Illness</condition>
  <condition>Respiratory Acidosis</condition>
  <condition>Respiratory Alkalosis</condition>
  <condition>Acid-Base Imbalance</condition>
  <arm_group>
    <arm_group_label>Septic patients</arm_group_label>
    <description>Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Age and sex matched healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non septic patients</arm_group_label>
    <description>Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.</intervention_name>
    <description>Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non septic patients</arm_group_label>
    <arm_group_label>Septic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood</intervention_name>
    <description>Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non septic patients</arm_group_label>
    <arm_group_label>Septic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biomolecular analysis of plasma proteins.</intervention_name>
    <description>Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Non septic patients</arm_group_label>
    <arm_group_label>Septic patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples in ethylenediaminetetraacetic acid for subsequent biomolecular analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with sepsis or septic shock admitted to the ICU

          2. Healthy volunteers recruited from ICU staff members and relatives

          3. Non-septic patients admitted to the ICU after elective surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1: Septic patients

        Inclusion Criteria for Group 1:

          -  Diagnosis of Sepsis

          -  Age &gt; 18 years

          -  Informed or deferred informed consent

        Exclusion Criteria for Group 1:

          -  Pregnancy

          -  Bilirubin &gt; 4 mg/dL

          -  Minor or major thalassemia

          -  Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during
             the 24 hours prior to enrollment

        Group 2: Healthy volunteers

        Inclusion criteria for Group 2:

          -  informed consent

          -  Age &gt; 18 years

        Exclusion criteria for Group 2:

        â€¢ Pregnancy

        Group 3: Non-septic patients

        Inclusion criteria for Group 3:

          -  Informed consent

          -  Age &gt;18 years

          -  Planned ICU admission after elective surgery

        Exclusion criteria for Group 3:

          -  Diagnosis of sepsis

          -  Pregnancy

          -  Bilirubin &gt;4 mg/dL

          -  Liver cirrhosis

          -  Onco-hematological diseases

          -  Minor or major thalassemia

          -  Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during
             the 24 hours prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Langer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Ca' Granda Hospital, Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio M Pesenti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frantisek Duska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third faculty of Medicine, Charles University, Prague</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giacomo Grasselli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Elbers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amsterdam UMC, Department of Intensive Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Langer, MD</last_name>
    <phone>0255033232</phone>
    <email>thomas.langer@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Third faculty of Medicine, Charles University of Prague</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frantisek Duska, MD</last_name>
      <email>fduska@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Frantisek Duska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Krbec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petr Waldauf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomas Urban, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Langer, MD</last_name>
      <phone>025503</phone>
      <phone_ext>3232</phone_ext>
      <email>Thomas.Langer@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Thomas Langer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serena Brusatori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Mauro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Brambilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Henderson LJ. THE REGULATION OF NEUTRALITY IN THE ANIMAL BODY. Science. 1913 Mar 14;37(950):389-95.</citation>
    <PMID>17795147</PMID>
  </reference>
  <reference>
    <citation>Lee SW, Hong YS, Park DW, Choi SH, Moon SW, Park JS, Kim JY, Baek KJ. Lactic acidosis not hyperlactatemia as a predictor of in hospital mortality in septic emergency patients. Emerg Med J. 2008 Oct;25(10):659-65. doi: 10.1136/emj.2007.055558.</citation>
    <PMID>18843064</PMID>
  </reference>
  <reference>
    <citation>Fencl V, Leith DE. Stewart's quantitative acid-base chemistry: applications in biology and medicine. Respir Physiol. 1993 Jan;91(1):1-16. Review.</citation>
    <PMID>8441866</PMID>
  </reference>
  <reference>
    <citation>LEEUWEN AM. NET CATION EQUIVALENCY ('BASE BINDING POWER') OF THE PLASMA PROTEINS. Acta Med Scand. 1964;176:SUPPL 422: 1+.</citation>
    <PMID>14204741</PMID>
  </reference>
  <reference>
    <citation>Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med. 1992 Nov;120(5):713-9.</citation>
    <PMID>1431499</PMID>
  </reference>
  <reference>
    <citation>Stampfli HR, Misiaszek S, Lumsden JH, Carlson GP, Heigenhauser GJ. Weak acid-concentration Atot and dissociation constant Ka of plasma proteins in racehorses. Equine Vet J Suppl. 1999 Jul;(30):438-42.</citation>
    <PMID>10659296</PMID>
  </reference>
  <reference>
    <citation>Staempfli HR, Constable PD. Experimental determination of net protein charge and A(tot) and K(a) of nonvolatile buffers in human plasma. J Appl Physiol (1985). 2003 Aug;95(2):620-30. Epub 2003 Mar 28.</citation>
    <PMID>12665532</PMID>
  </reference>
  <reference>
    <citation>Langer T, Scotti E, Carlesso E, Protti A, Zani L, Chierichetti M, Caironi P, Gattinoni L. Electrolyte shifts across the artificial lung in patients on extracorporeal membrane oxygenation: interdependence between partial pressure of carbon dioxide and strong ion difference. J Crit Care. 2015 Feb;30(1):2-6. doi: 10.1016/j.jcrc.2014.09.013. Epub 2014 Sep 22.</citation>
    <PMID>25307980</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acid-base equilibrium; pH; septic shock; critical illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acidosis, Respiratory</mesh_term>
    <mesh_term>Alkalosis, Respiratory</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Alkalosis</mesh_term>
    <mesh_term>Acid-Base Imbalance</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

